Clinical Guides
Insulin Therapy in Diabetes
A clinically focused practical guide to recognising when insulin is needed, initiating and titrating it safely, teaching injection and storage, preventing hypoglycaemia, and managing illness, pregnancy, renal impairment and care transitions in India.
MedNext Academy | 14 min read
Insulin Therapy in Diabetes
A clinically focused practical guide to recognising when insulin is needed, initiating and titrating it safely, teaching injection and storage, preventing hypoglycaemia, and managing illness, pregnancy, renal impairment and care transitions in India.
Summary
Insulin therapy replaces or supplements endogenous insulin and is indispensable in type 1 diabetes, diabetic ketoacidosis, hyperosmolar crisis with appropriate timing, and many pregnancies complicated by diabetes. It is also appropriate in type 2 diabetes when marked symptomatic hyperglycaemia, catabolism, acute decompensation, contraindications to alternatives, or persistent glucose above an individualised target makes non-insulin treatment insufficient. Starting insulin is not evidence of personal failure. It is a physiological treatment whose benefit depends on matching the preparation and regimen to the person's diabetes type, meals, work, kidney function, dexterity, monitoring capacity, hypoglycaemia risk, and ability to obtain an uninterrupted supply.
Safe initiation is a process rather than a prescription alone. Confirm the indication and likely diabetes type; agree glucose and HbA1c goals; choose a delivery system the person can use; demonstrate injection, site rotation, storage, and sharps disposal; provide a written titration and hypoglycaemia plan; and arrange early review. Basal insulin is a common first insulin in type 2 diabetes. A basal-bolus, pump, or other intensive replacement strategy is generally required when endogenous insulin is absent. Premixed insulin can reduce injection complexity but imposes more rigid meal timing and is not automatically safer.
The greatest preventable harms are wrong-product or wrong-concentration errors, hypoglycaemia, omitted basal insulin in insulin-deficient diabetes, inappropriate escalation when fasting glucose is already controlled, and loss of continuity after illness or discharge. This guide explains principles for trained clinicians and learners; it cannot replace patient-specific prescribing, a locally ratified titration protocol, pregnancy specialist input, or emergency pathways.
How Common Is It?
The number of people who use insulin cannot be inferred directly from diabetes prevalence. Everyone with type 1 diabetes requires insulin, whereas the proportion with type 2 diabetes changes with duration, case mix, treatment access, local thresholds, and the availability of effective non-insulin medicines. People may need insulin transiently during severe infection, surgery, glucocorticoid exposure, pregnancy, enteral or parenteral feeding, or hyperglycaemic crisis, then return to a simpler plan after the precipitating problem resolves. Others need permanent intensification because beta-cell function has declined.
Indian estimates are especially sensitive to where measurement occurs. Specialist clinics see more complex regimens than primary-care registers, and prescription datasets miss people who cannot afford or consistently obtain insulin. Hospital use does not equal community use. Older ICMR guidance remains useful for service design but cannot provide a current national percentage for every state, payer, and care setting. A responsible guide therefore avoids a fabricated insulin-use figure.
Services should instead measure actionable outcomes: time from a clear indication to initiation, severe and nocturnal hypoglycaemia, recurrent ketoacidosis, missed doses caused by supply, injection-site assessment, access to strips and needles, and follow-up after discharge. A high prescribing rate is not a quality marker by itself. Quality means the right insulin for the right indication, with education, monitoring, affordability, and a reliable path for dose review.
Risk Factors
The clinical drivers for insulin differ by diabetes type. Absolute or near-absolute insulin deficiency is suggested by ketosis, rapid weight loss, polyuria, polydipsia, short symptom duration, personal or family autoimmunity, low or falling C-peptide interpreted alongside glucose, or failure of non-insulin therapy that is too rapid for ordinary type 2 progression. Age and body size do not reliably exclude type 1 diabetes. Pancreatic destruction, pancreatectomy, cystic-fibrosis-related diabetes, immune-checkpoint-inhibitor diabetes, and some monogenic disorders may also create a strong or immediate need.
In established type 2 diabetes, insulin becomes more likely with very high glucose or HbA1c, osmotic symptoms, catabolism, long duration, intercurrent illness, glucocorticoids, pregnancy, advanced liver or kidney disease that narrows medicine choices, or inability to tolerate effective alternatives. The ADA advises considering initiation when symptoms are present or when HbA1c is above 10% or glucose at least 300 mg/dL, while still excluding crisis and individualising the decision. Those thresholds are prompts, not permission to manage an unstable patient at home.
Factors that raise treatment harm must be assessed before the first dose: prior severe hypoglycaemia, impaired awareness, irregular meals, alcohol, frailty, cognitive or visual impairment, manual-dexterity problems, CKD, changing renal function, shift work, driving, food insecurity, and poor access to monitoring. Lipohypertrophy and inconsistent injection technique create erratic absorption. Cost-driven rationing, counterfeit supply, heat exposure, and inability to refrigerate unopened stock are clinical risks, not merely social background.
Diagnosis
History
Clarify the diabetes type, duration, current medicines, previous insulin exposure, hyperglycaemic symptoms, weight trajectory, ketones or crises, pregnancy possibility, steroid use, pancreatitis or pancreatic surgery, kidney and liver disease, cardiovascular disease, eating pattern, fasting practices, physical activity, occupation, driving, alcohol, and episodes suggestive of hypoglycaemia. Ask exactly what the person can afford and obtain, who administers doses, where insulin is stored, and whether vision, cognition, literacy, numeracy, or hand function affects safe use. Reconcile the product name, concentration, device, units, timing, and actual technique rather than accepting “insulin” as a complete medication history.
Examination
Assess hydration, ketotic breathing, mental state, and haemodynamic stability before treating this as routine initiation. Record weight and recent change, blood pressure, injection sites, lipohypertrophy, bruising, infection, and the person's ability to see the dose window and operate the chosen device. Look for neuropathy, foot ulceration, peripheral arterial disease, retinopathy-related visual limitation, and signs of endocrine or pancreatic disease when relevant.
Investigations
Obtain capillary or plasma glucose and HbA1c when interpretable, but test blood ketones, venous blood gas, electrolytes, and osmolality urgently if crisis is possible. Renal and liver function influence regimen and monitoring. Consider urine albumin-creatinine ratio, lipids, pregnancy testing, and complication assessment. C-peptide and diabetes autoantibodies can support classification in selected stable patients but must not delay insulin when deficiency is clinically likely. Establish a baseline glucose pattern using meter readings or CGM where accessible; never titrate from HbA1c alone because it conceals timing and hypoglycaemia.
Differential Diagnosis
Before escalating insulin, decide whether the apparent problem is insufficient dose, an unsuitable regimen, or something else. Persistent high glucose may reflect omitted doses, an empty or damaged cartridge, heat exposure, injection into lipohypertrophy, wrong needle technique, expired stock, device failure, timing mismatch, glucocorticoids, infection, myocardial infarction, pregnancy, or progressive insulin deficiency. Apparent resistance can arise from inaccurate meter readings, hidden carbohydrate intake, severe sleep disruption, endocrinopathy, or drugs that increase glucose. These possibilities require respectful assessment, not an accusation of non-adherence.
Recurrent low glucose may represent excessive basal insulin, a missed or delayed meal, unplanned exercise, alcohol, reduced renal clearance, weight loss, recovery from acute illness, postpartum physiology, or a dosing/concentration error. Nocturnal hypoglycaemia followed by morning hyperglycaemia should not be assumed to be a rebound phenomenon without overnight data. If fasting glucose is at target but HbA1c remains high, escalating basal insulin can produce overnight hypoglycaemia while leaving post-meal glucose untreated; examine the whole daily pattern.
Diagnostic classification also matters. Type 1 diabetes, ketosis-prone diabetes, latent autoimmune diabetes in adults, monogenic diabetes, pancreatic diabetes, and stress hyperglycaemia can be mistaken for ordinary type 2 disease. DKA and HHS are emergency differentials when symptoms, ketones, acidosis, dehydration, or altered consciousness appear. In hospital, distinguish persistent diabetes from transient stress or steroid-related hyperglycaemia, but plan follow-up because both predict future risk.
Management
Begin with a shared objective and a regimen that the person can perform consistently. In type 1 diabetes, physiological replacement normally combines background basal insulin with prandial insulin, supported by carbohydrate education, correction principles, monitoring, and ketone and sick-day rules. In stable type 2 diabetes needing a first injectable, current guidance generally prefers GLP-1-based therapy before insulin when there is no severe hyperglycaemia or crisis and access permits. Insulin is appropriate when symptoms, catabolism, very high glucose, pregnancy, acute decompensation, or individual constraints make it the safer choice.
Basal insulin is the simplest common start for type 2 diabetes. ADA guidance describes an initial estimate of 0.1–0.2 units/kg/day, adjusted for hyperglycaemia and patient factors; a fixed low starting dose may be used in some local protocols. Use a written fasting-glucose titration algorithm with small, scheduled adjustments and explicit rules to reduce for hypoglycaemia. Review within days to weeks, not months. If fasting values reach goal while HbA1c or daytime glucose remains high, assess meals and add targeted prandial therapy or another suitable agent instead of indefinitely raising basal insulin. Reassess sulfonylureas and other hypoglycaemia-producing drugs.
Teach injection with demonstration and return-demonstration: correct insulin and concentration, new compatible needle, priming where the device requires it, subcutaneous delivery, adequate dwell time, site rotation within abdomen or other approved sites, and avoidance of lipohypertrophic tissue. Never share pens, even if the needle is changed. Provide written treatment for low glucose, access to glucagon where indicated, medical identification, driving advice, and instructions for fasting and exercise.
During illness, monitor glucose more frequently, maintain fluids and carbohydrate as tolerated, and check ketones when insulin deficiency, symptoms, or SGLT2 inhibitor exposure makes DKA possible. A person with type 1 diabetes must not stop basal insulin because they are not eating. Vomiting, rising ketones, breathing difficulty, dehydration, or inability to keep fluids down requires urgent assessment. Any sick-day dose changes must follow the person's agreed plan rather than a generic online formula.
Prescribing Information
Write insulin by brand or unambiguous generic descriptor, concentration, device, dose in full units, route, and timing. Never abbreviate “units” as U or IU. Confirm that the pen, cartridge, vial, needle, and syringe are compatible; a U-100 syringe must not be used to measure a concentrated insulin. Products with similar names may have different actions or strengths. Prescribers must check current Indian product information and formulary availability because brands, concentrations, biosimilars, and devices change.
Match pharmacology to the clinical problem. Basal preparations chiefly restrain glucose between meals and overnight; rapid or short-acting preparations cover meals and corrections; premixed products combine components but reduce flexibility. NPH and human regular insulin can be effective, lower-cost options when supported by education and predictable meals. Long-acting analogues may reduce nocturnal or clinically significant hypoglycaemia in selected people but can cost more. WHO's low-resource guidance emphasises that human insulin remains an appropriate essential option and that analogue choice should consider severe hypoglycaemia risk and resources.
Storage instructions must follow the specific manufacturer's label. In general, protect insulin from freezing, excessive heat, and direct sunlight; discard frozen insulin. Unopened supplies usually require refrigeration within the labelled range. Once in use, allowable room temperature and duration vary by product, so write the opening date and do not apply one “28-day” rule to every formulation. In hot Indian conditions, discuss transport, power cuts, insulated—not ice-contact—carriage, and how to obtain replacement if exposure or appearance is concerning. Do not improvise earthen-pot storage without a product- and service-approved method.
Renal impairment can reduce insulin clearance and appetite, increasing hypoglycaemia; dose needs may fall as kidney function deteriorates or after dialysis-related changes. Liver disease, weight loss, and frailty also justify conservative adjustment. Pregnancy needs specialist-led selection and frequent titration; insulin requirements can rise later in gestation and fall sharply after delivery. Document needles, strips, lancets, ketone testing, glucagon where appropriate, sharps disposal, education, monitoring frequency, titration ownership, and supply continuity as part of the prescription.
When to Refer
Arrange emergency care for suspected DKA or HHS, persistent vomiting, significant ketonaemia, deep breathing, severe dehydration, altered mental state, shock, sepsis with metabolic instability, or severe hypoglycaemia that requires assistance and does not promptly resolve. A new presentation suggesting type 1 diabetes requires same-day specialist-supported assessment; do not delay for outpatient antibody or C-peptide results. An insulin user who cannot obtain insulin today needs an urgent practical supply plan.
Refer promptly to a diabetes team when diagnosis is uncertain, glycaemia remains unstable despite verified technique and adherence, severe or nocturnal hypoglycaemia recurs, awareness is impaired, pregnancy is planned or confirmed, or pump, CGM, concentrated insulin, complex basal-bolus therapy, or transition from intravenous insulin requires expertise. Advanced CKD, dialysis, severe liver disease, recurrent hospital admission, eating disorder, cognitive decline, or inability of the person or caregiver to deliver insulin safely also justifies multidisciplinary input.
Injection-site abscess, widespread lipohypertrophy with unpredictable absorption, active diabetic foot disease, sudden visual change, or major cardiovascular symptoms need the corresponding urgent pathway. Referral must include the exact current product, dose, recent glucose and ketone data, kidney function, hypoglycaemia history, clinical question, urgency, and who will act on interim results. Specialist referral does not remove primary-care responsibility for prescriptions, consumables, education, and follow-up.
Red Flags
Metabolic emergency features include vomiting, abdominal pain, marked thirst, polyuria followed by oliguria, dehydration, Kussmaul breathing, fruity breath, drowsiness, confusion, hypotension, and positive blood ketones. DKA can occur at a lower glucose than expected, particularly in pregnancy and with SGLT2 inhibitors. A person using insulin who is unwell with rising ketones must not simply take repeated unsupervised correction doses while delaying assessment.
Hypoglycaemia warning signs include sweating, tremor, hunger, palpitations, behavioural change, confusion, visual disturbance, seizure, and unconsciousness. Neurogenic symptoms may be absent in impaired awareness. Any episode requiring another person's assistance is severe and must trigger urgent review of the regimen, kidney function, meals, alcohol, driving, and access to glucagon. Repeated overnight lows, unexplained falls, or a low during safety-critical work are not acceptable trade-offs for a lower HbA1c.
Medication red flags include an uncertain concentration, a pen that belongs to somebody else, dose instruction written in millilitres without verified conversion, use of a syringe that does not match the vial, abrupt switch between products, frozen or heat-damaged stock, and recurrent high glucose after starting a new vial. Pregnancy, postpartum change, acute kidney injury, prolonged fasting, and discharge after intravenous insulin are high-risk transitions. Omitting basal insulin in type 1 diabetes, using correction-only insulin in most hospitalised patients, or discharging without medicine reconciliation, education, supplies, and follow-up can cause preventable crisis.
Indian Clinical Context
India combines high diabetes burden with major variation in specialist access, insurance, procurement, electricity, food security, and glucose-monitoring availability. A regimen that depends on an unaffordable analogue, unavailable pen needle, or daily strip frequency the household cannot sustain is unsafe, even if pharmacologically elegant. Ask about out-of-pocket cost and travel before prescribing. Where human insulin is the reliable option, provide the additional meal-timing and hypoglycaemia education it requires rather than presenting it as inferior care. Where an analogue offers a meaningful safety advantage, document why and verify continuity.
Primary-care teams should connect insulin initiation to the NP-NCD pathway, complication screening, and a named escalation route. Community health workers may reinforce appointment recall, storage checks, and recognition of danger signs when the patient consents and privacy is protected; they do not replace a trained prescriber. Each centre needs a protocol for initiation, dose communication, sharps, cold-chain breaks, emergency replacement, fasting during religious observance, travel, and transfer between public and private prescriptions.
Heat and power interruption demand product-specific counselling. Unopened insulin normally needs the labelled cold chain, must never freeze, and should not touch ice directly during travel. The usable life of opened stock is formulation-specific. Verify the leaflet rather than repeating a universal duration. Write opening dates, inspect for unexpected particles or altered appearance according to product type, and replace stock when temperature integrity is doubtful and glucose response changes.
Use culturally and economically realistic meal plans. A person doing physical labour, rotating night shifts, or fasting needs an individual plan before dose change. Language, numeracy, vision, and family roles affect safe technique. Record return-demonstration rather than “counselled.” Access limitations should prompt the safest workable regimen and transparent referral, never omission of essential insulin or an unsupported claim that expensive technology is necessary for good care.
NMC Competency Mapping
Insulin therapy integrates the NMC Medicine diabetes outcomes concerning presentation, investigation, chronic complications, emergencies, and pharmacotherapy. IM11.15 covers recognition and initial principles for diabetic emergencies, while IM11.16 addresses classes, indications, pharmacology, adverse effects, interactions, and monitoring of diabetes medicines. The guide also supports IM11.9 and IM11.11 by linking symptoms, glucose, electrolytes, ketones, blood gas, renal function, and classification to treatment decisions. Exact wording and required performance level must be checked against the institution's authorised 2024 curriculum ledger.
A competent learner should explain basal, prandial, premixed, and intravenous roles; identify when insulin is essential; recognise hypoglycaemia and crisis; prescribe without unsafe abbreviations; and demonstrate injection, site rotation, storage, meter use, and sharps disposal under supervision. Learners should be able to interpret a glucose pattern, distinguish fasting from post-meal failure, and propose a review plan without inventing a patient-specific dose. Pregnancy, paediatric type 1 diabetes, pumps, concentrated insulin, and intravenous-to-subcutaneous transition require appropriate supervision.
Assessment can use an OSCE in which the candidate verifies a pen and prescription, teaches injection, detects lipohypertrophy, and gives hypoglycaemia and sick-day safety-netting. A written case can test why repeatedly increasing basal insulin is unsafe when fasting glucose is controlled. Passing an educational station does not confer authority to independently initiate complex insulin, manage DKA, or approve this quarantined guide for publication.
Key Exam Pearls for NEET PG
Insulin is mandatory in type 1 diabetes and is used in DKA, selected HHS phases, pregnancy, severe symptomatic hyperglycaemia, and type 2 diabetes not safely controlled by other approaches. Basal insulin suppresses hepatic glucose output between meals and overnight; prandial insulin addresses meal-related excursions. In type 2 diabetes, a common basal starting estimate is 0.1–0.2 units/kg/day, but the final prescription and titration are individualised. If fasting glucose is controlled and HbA1c remains high, think postprandial hyperglycaemia or an alternative explanation rather than endless basal escalation.
Hypoglycaemia is the central acute adverse effect. Renal impairment, missed meals, exercise, alcohol, weight loss, and recovery from illness may lower dose requirement. Repeated injection into lipohypertrophy causes variable absorption. Rotate within and between recommended sites, use the correct device, and never share a pen. “U” and “IU” are unsafe abbreviations. Concentrated insulin creates major error potential if the device and dose are misunderstood.
Never stop basal insulin in type 1 diabetes during fasting or illness. Check ketones when DKA is possible; SGLT2-associated DKA may be euglycaemic. In hospital, correction-only sliding-scale treatment is discouraged for most patients; basal plus nutritional and correction components are matched to intake and illness. Overlap is needed when moving from intravenous to subcutaneous basal insulin under protocol. Pregnancy increases the need for frequent monitoring and specialist titration, and insulin requirements fall abruptly postpartum. Unopened insulin is protected by the labelled cold chain; freezing destroys usability, while in-use limits depend on the exact product.
Frequently Asked Questions
Does starting insulin mean that a person with type 2 diabetes has failed?
No. Type 2 diabetes is progressive and insulin secretion often declines over time. Insulin may also be the safest temporary treatment during illness, pregnancy, surgery, or marked symptomatic hyperglycaemia. The decision should be explained as matching treatment to physiology, while addressing cost, monitoring, hypoglycaemia, and the possibility of later simplification when appropriate.
Can basal insulin be increased whenever an HbA1c result remains above target?
Not safely. Review fasting, daytime, and post-meal glucose, low readings, technique, adherence, meals, and kidney function. If fasting glucose is already at target, more basal insulin may cause nocturnal hypoglycaemia without correcting postprandial elevation. The regimen or non-insulin treatment may need a different, patient-specific change.
Should insulin be stopped when a person with type 1 diabetes cannot eat during illness?
Basal insulin must not be stopped in type 1 diabetes because insulin deficiency can rapidly cause ketoacidosis even without food. Glucose and ketones require more frequent monitoring, fluids and carbohydrate are used as tolerated, and dose changes follow the individual sick-day plan. Vomiting, rising ketones, breathing difficulty, or dehydration needs urgent assessment.
How long can an opened insulin pen or vial remain outside a refrigerator?
There is no single duration for every insulin. Temperature limits and in-use life differ by brand, formulation, and device. Follow the current manufacturer leaflet, record the opening date, protect from direct heat and sunlight, and never freeze insulin. In hot conditions or after a cold-chain failure, seek product-specific advice and replace questionable stock when feasible.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic